Adam Feuerstein

Adam Feuerstein completed a bachelor's degree in political science at Emory University.[1]

Feuerstein covered business, technology, and commercial real estate for the San Francisco Business Times and the Atlanta Business Chronicle as an assistant managing editor.[1][2] He later wrote about business software for Upside.com. In March 2001, he joined TheStreet.com. From 2005 to 2006 he worked as a research analyst for a hedge fund before returning to TheStreet. He resigned in May 2017. Feuerstein accepted a position as a national biotechnology columnist at STAT in June 2017.[1]

Feuerstein is known for his style of reporting and his tweets to his large Twitter following.[3][4] He often shares "unabashed" views on Biotech stock and the Food and Drug Administration.[5]

Feuerstein has been accused of publishing false or embellished stories in an effort to claim relevance as a journalist and bully companies, most recently in a series of attack stories on a company involved in testing the treatment Leronlimab on severe and critical COVID-19 patients.[6] On July 13th, Cytodyn held an investor conference call[7] where the company declared they fulfill all the requirements for Nasdaq uplisting and the application is ready to be submitted. Same day Feuerstein tweeted "Cytodyn admitted on Monday’s call that it doesn’t meet NASDAQ listing requirements, but announcing things that never happen, like multiple clinical trials and FDA approval submissions, is a deliberate stock-pumping strategy.". The tweet caused anger among shareholders who attended the meeting. Two days later Cytodyn filed Nasdaq uplisting application.[8] Feuerstein has repeatedly been accused of lacking credibility when reporting on clinical trial outcomes given his lack of scientific background academically and professionally. Feuerstein is often the subject of criticism from different parties in the biotechnology sector.[9]